Limits...
Graphene as cancer theranostic tool: progress and future challenges.

Orecchioni M, Cabizza R, Bianco A, Delogu LG - Theranostics (2015)

Bottom Line: In this scenario nanomaterials could be good allies to give more specific cancer treatment effectively reducing undesired side effects and giving at the same time accurate diagnosis and successful therapy.Part of the works here discussed contribute to the growth of the theranostic field covering the use of imaging (i.e. ultrasonography, positron electron tomography, and fluorescent imaging) combined to one or more therapeutic modalities.Any technology based on nanomaterials can significantly enhance their possibility to became the real revolution in medicine if combines diagnosis and therapy at the same time.

View Article: PubMed Central - PubMed

Affiliation: 1. Department of Chemistry and Pharmacy, University of Sassari , via muroni 23 07100 Sassari, Italy.

ABSTRACT
Nowadays cancer remains one of the main causes of death in the world. Current diagnostic techniques need to be improved to provide earlier diagnosis and treatment. Traditional therapy approaches to cancer are limited by lack of specificity and systemic toxicity. In this scenario nanomaterials could be good allies to give more specific cancer treatment effectively reducing undesired side effects and giving at the same time accurate diagnosis and successful therapy. In this context, thanks to its unique physical and chemical properties, graphene, graphene oxide (GO) and reduced graphene (rGO) have recently attracted tremendous interest in biomedicine including cancer therapy. Herein we analyzed all studies presented in literature related to cancer fight using graphene and graphene-based conjugates. In this context, we aimed at the full picture of the state of the art providing new inputs for future strategies in the cancer theranostic by using of graphene. We found an impressive increasing interest in the material for cancer therapy and/or diagnosis. The majority of the works (73%) have been carried out on drug and gene delivery applications, following by photothermal therapy (32%), imaging (31%) and photodynamic therapy (10%). A 27% of the studies focused on theranostic applications. Part of the works here discussed contribute to the growth of the theranostic field covering the use of imaging (i.e. ultrasonography, positron electron tomography, and fluorescent imaging) combined to one or more therapeutic modalities. We found that the use of graphene in cancer theranostics is still in an early but rapidly growing stage of investigation. Any technology based on nanomaterials can significantly enhance their possibility to became the real revolution in medicine if combines diagnosis and therapy at the same time. We performed a comprehensive summary of the latest progress of graphene cancer fight and highlighted the future challenges and the innovative possible theranostic applications.

Show MeSH

Related in: MedlinePlus

Paper analysis in terms of percentage of manuscripts divided by type of applications and type of cancer.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4402495&req=5

Figure 5: Paper analysis in terms of percentage of manuscripts divided by type of applications and type of cancer.

Mentions: The good drug loading ability of graphene encouraged many researchers to explore it in many different types of cancer. According to the general trend, the most studied tumor, with 31% of the total works, is breast cancer (Figure 5A) 15, 32, 34, 36, 39-41, 43, 45, 49-51, 58, 65, 66, 72, 81, 86, 89, 92, followed by cervical cancer 35, 37, 42, 43, 52-54, 59, 63, 67, 68, 77, 78, 82, 89 and liver cancer 44, 55, 72-75, 79, 85, 88 with 23% and 10% respectively.


Graphene as cancer theranostic tool: progress and future challenges.

Orecchioni M, Cabizza R, Bianco A, Delogu LG - Theranostics (2015)

Paper analysis in terms of percentage of manuscripts divided by type of applications and type of cancer.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4402495&req=5

Figure 5: Paper analysis in terms of percentage of manuscripts divided by type of applications and type of cancer.
Mentions: The good drug loading ability of graphene encouraged many researchers to explore it in many different types of cancer. According to the general trend, the most studied tumor, with 31% of the total works, is breast cancer (Figure 5A) 15, 32, 34, 36, 39-41, 43, 45, 49-51, 58, 65, 66, 72, 81, 86, 89, 92, followed by cervical cancer 35, 37, 42, 43, 52-54, 59, 63, 67, 68, 77, 78, 82, 89 and liver cancer 44, 55, 72-75, 79, 85, 88 with 23% and 10% respectively.

Bottom Line: In this scenario nanomaterials could be good allies to give more specific cancer treatment effectively reducing undesired side effects and giving at the same time accurate diagnosis and successful therapy.Part of the works here discussed contribute to the growth of the theranostic field covering the use of imaging (i.e. ultrasonography, positron electron tomography, and fluorescent imaging) combined to one or more therapeutic modalities.Any technology based on nanomaterials can significantly enhance their possibility to became the real revolution in medicine if combines diagnosis and therapy at the same time.

View Article: PubMed Central - PubMed

Affiliation: 1. Department of Chemistry and Pharmacy, University of Sassari , via muroni 23 07100 Sassari, Italy.

ABSTRACT
Nowadays cancer remains one of the main causes of death in the world. Current diagnostic techniques need to be improved to provide earlier diagnosis and treatment. Traditional therapy approaches to cancer are limited by lack of specificity and systemic toxicity. In this scenario nanomaterials could be good allies to give more specific cancer treatment effectively reducing undesired side effects and giving at the same time accurate diagnosis and successful therapy. In this context, thanks to its unique physical and chemical properties, graphene, graphene oxide (GO) and reduced graphene (rGO) have recently attracted tremendous interest in biomedicine including cancer therapy. Herein we analyzed all studies presented in literature related to cancer fight using graphene and graphene-based conjugates. In this context, we aimed at the full picture of the state of the art providing new inputs for future strategies in the cancer theranostic by using of graphene. We found an impressive increasing interest in the material for cancer therapy and/or diagnosis. The majority of the works (73%) have been carried out on drug and gene delivery applications, following by photothermal therapy (32%), imaging (31%) and photodynamic therapy (10%). A 27% of the studies focused on theranostic applications. Part of the works here discussed contribute to the growth of the theranostic field covering the use of imaging (i.e. ultrasonography, positron electron tomography, and fluorescent imaging) combined to one or more therapeutic modalities. We found that the use of graphene in cancer theranostics is still in an early but rapidly growing stage of investigation. Any technology based on nanomaterials can significantly enhance their possibility to became the real revolution in medicine if combines diagnosis and therapy at the same time. We performed a comprehensive summary of the latest progress of graphene cancer fight and highlighted the future challenges and the innovative possible theranostic applications.

Show MeSH
Related in: MedlinePlus